U.S. drug major Eli Lilly and Company is planning to strengthen its presence in India by introducing at least one drug every year for the next four years in the areas of diabetes, oncology, osteoporosis and growth disorder, said a top official.
Eli Lilly and Company (India) Pvt. Ltd. Managing Director Edgard Olaizola said: “About 50 drugs are under various stages of trials out of which seven are undergoing phase three of clinical trials. It is difficult to say which drug will be released when as we have to get regulatory/agencies’ approvals. We will roll out a diabetic drug by the year end and an oncology drug next year.”
Mr. Olaizolasaid the pipeline of new drugs included thoseprescribed for stomach and breast cancer and pain management.About 80 per cent of revenue for the Indian unit comes from diabetes drugs and the balance from those prescribed for cancer, osteoporosis and other conditions.
“Trulicity, a once-a-week single dose diabetic injectible drug, is being imported from the U.S. and is priced Rs.2,499 per injection. It is an important addition to our diabetes portfolio in India and Tamil Nadu is one of our key markets,” he said.
